Recent Investment Analysts’ Ratings Updates for ORIC Pharmaceuticals (ORIC)

Posted by Tyrone Williams on Mar 4th, 2025

ORIC Pharmaceuticals (NASDAQ: ORIC) has recently received a number of price target changes and ratings updates:

2/26/2025 – ORIC Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $21.00 to $22.00. They now have an “overweight” rating on the stock.
2/26/2025 – ORIC Pharmaceuticals had its “buy” rating reaffirmed by analysts at Guggenheim.
2/21/2025 – ORIC Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
2/11/2025 – ORIC Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
2/10/2025 – ORIC Pharmaceuticals had its “buy” rating reaffirmed by analysts at Guggenheim.
2/6/2025 – ORIC Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an “overweight” rating on the stock.
1/14/2025 – ORIC Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
1/13/2025 – ORIC Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
1/13/2025 – ORIC Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.

ORIC Pharmaceuticals Trading Down 4.9 %

NASDAQ ORIC opened at $7.64 on Tuesday. The stock has a 50-day simple moving average of $9.26 and a 200 day simple moving average of $9.47. The company has a market capitalization of $542.65 million, a PE ratio of -4.20 and a beta of 1.21. ORIC Pharmaceuticals, Inc. has a 12 month low of $6.33 and a 12 month high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.01. As a group, sell-side analysts predict that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Insider Activity at ORIC Pharmaceuticals

In other ORIC Pharmaceuticals news, insider Pratik S. Multani sold 8,850 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $73,278.00. Following the completion of the transaction, the insider now directly owns 46,765 shares of the company’s stock, valued at approximately $387,214.20. The trade was a 15.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jacob Chacko sold 24,660 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $204,184.80. Following the completion of the transaction, the chief executive officer now directly owns 778,648 shares of the company’s stock, valued at approximately $6,447,205.44. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,361 shares of company stock worth $350,749. 5.55% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alkeon Capital Management LLC grew its stake in ORIC Pharmaceuticals by 2.6% in the third quarter. Alkeon Capital Management LLC now owns 3,904,096 shares of the company’s stock valued at $40,017,000 after acquiring an additional 100,000 shares during the period. Vanguard Group Inc. grew its stake in ORIC Pharmaceuticals by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 3,203,789 shares of the company’s stock valued at $25,855,000 after acquiring an additional 36,478 shares during the period. Boxer Capital Management LLC acquired a new position in shares of ORIC Pharmaceuticals during the fourth quarter worth about $13,982,000. NEA Management Company LLC boosted its position in shares of ORIC Pharmaceuticals by 4.4% during the fourth quarter. NEA Management Company LLC now owns 1,566,081 shares of the company’s stock worth $12,638,000 after buying an additional 66,081 shares during the period. Finally, Balyasny Asset Management L.P. boosted its position in shares of ORIC Pharmaceuticals by 37.5% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,555,260 shares of the company’s stock worth $12,551,000 after buying an additional 424,194 shares during the period. 95.05% of the stock is owned by institutional investors and hedge funds.

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.